Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 14/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.55 |
| ▸ | PLG | P00747 | 2/20 | 0.54 |
| ▸ | PROC | P04070 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7122636 | 0.83 | F10 (0.49) | F10PRSS1F2 | |
| SCHEMBL7127217 | 0.80 | F10 (0.65) | F10PRSS1PLGPROCF2 | |
| SCHEMBL6807634 | 0.76 | F10 (0.75) | F10PRSS1PLGPROCPRSS2 | |
| SCHEMBL7125640 | 0.75 | LMNA (0.51) | LMNAMAPTTHRB | |
| SCHEMBL7128378 | 0.74 | GAA (0.43) | F10PRSS1LMNAF2MAPT | |
| SCHEMBL18360800 | 0.71 | THRB (0.84) | LMNAMAPTTHRB | |
| SCHEMBL20527883 | 0.71 | THRB (0.84) | LMNAMAPTTHRB | |
| SCHEMBL7118516 | 0.71 | F10 (1.00) | F10PRSS1PLGPROCF2 | |
| SCHEMBL7126469 | 0.70 | KDM4E (0.56) | LMNAMAPTTHRB | |
| SCHEMBL7114469 | 0.70 | F10 (0.70) | F10PRSS1PLGPROCF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114448-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2003-06-19 | — | — | US | disclosed |
| WO-2002096873-A1 | ISOINDOLE AND ISOQUINOLINE DERIVATIVES AS INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114448-A1 | Inhibitors of factor Xa | SERPINC1, F11, TFPI | F10 7/4885PRSS1 59/4885PLG 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.